RT Journal Article
SR Electronic
T1 Transfer transcriptomic signatures for infectious diseases
JF medRxiv
FD Cold Spring Harbor Laboratory Press
SP 2020.09.28.20203406
DO 10.1101/2020.09.28.20203406
A1 Iulio, Julia di
A1 Bartha, Istvan
A1 Spreafico, Roberto
A1 Virgin, Herbert W.
A1 Telenti, Amalio
YR 2020
UL http://medrxiv.org/content/early/2020/09/29/2020.09.28.20203406.abstract
AB The modulation of the transcriptome is among the earliest responses to infection, and vaccination. However, defining transcriptome signatures of disease is challenging because logistic, technical and cost factors limit the size and representativeness of samples in clinical studies. These limitations lead to poor performance of signatures when applied to new datasets or varying study settings. Using a novel approach, we leverage existing transcriptomic signatures as classifiers in unseen datasets from prospective studies, with the goal of predicting individual outcomes. Machine learning allowed the identification of sets of genes, which we name transfer transcriptomic signatures, that are predictive across diverse datasets and/or species (rhesus to humans) and that are also suggestive of activated pathways and cell type composition. We demonstrate the usefulness of transfer signatures in two use cases: progression of latent to active tuberculosis, and severity of COVID-19 and influenza A H1N1 infection. The broad significance of our work lies in the concept that a small set of archetypal human immunophenotypes, captured by transfer signatures, can explain a larger set of responses to diverse diseases.Competing Interest StatementEmployees of Vir Biotechnology Inc.Funding StatementVir Biotechnology Inc.Author DeclarationsI confirm all relevant ethical guidelines have been followed, and any necessary IRB and/or ethics committee approvals have been obtained.YesThe details of the IRB/oversight body that provided approval or exemption for the research described are given below:NA - this study uses public dataAll necessary patient/participant consent has been obtained and the appropriate institutional forms have been archived.YesI understand that all clinical trials and any other prospective interventional studies must be registered with an ICMJE-approved registry, such as ClinicalTrials.gov. I confirm that any such study reported in the manuscript has been registered and the trial registration ID is provided (note: if posting a prospective study registered retrospectively, please provide a statement in the trial ID field explaining why the study was not registered in advance).YesI have followed all appropriate research reporting guidelines and uploaded the relevant EQUATOR Network research reporting checklist(s) and other pertinent material as supplementary files, if applicable.YesData and code will be made available in Github upon publication